153 related articles for article (PubMed ID: 35922251)
41. Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
[TBL] [Abstract][Full Text] [Related]
42. Current and emerging immunotherapies for recurrent cervical cancer.
Liu MC; Tewari KS
Clin Adv Hematol Oncol; 2022 Feb; 20(2):108-115. PubMed ID: 35120091
[TBL] [Abstract][Full Text] [Related]
43. Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629.
Hughes BGM; Mendoza RG; Basset-Seguin N; Vornicova O; Schachter J; Joshi A; Meyer N; Grange F; Piulats JM; Bauman JR; Chirovsky D; Zhang P; Gumuscu B; Swaby RF; Grob JJ
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1777-1790. PubMed ID: 34558040
[TBL] [Abstract][Full Text] [Related]
44. First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness.
Zhang M; Liu X; Wen F; Wu Q; Zhou K; Bai L; Li Q
Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):e123-e129. PubMed ID: 34736841
[TBL] [Abstract][Full Text] [Related]
45. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
Migden MR; Khushalani NI; Chang ALS; Lewis KD; Schmults CD; Hernandez-Aya L; Meier F; Schadendorf D; Guminski A; Hauschild A; Wong DJ; Daniels GA; Berking C; Jankovic V; Stankevich E; Booth J; Li S; Weinreich DM; Yancopoulos GD; Lowy I; Fury MG; Rischin D
Lancet Oncol; 2020 Feb; 21(2):294-305. PubMed ID: 31952975
[TBL] [Abstract][Full Text] [Related]
46. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
[TBL] [Abstract][Full Text] [Related]
47. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
48. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).
Rittmeyer A; Gorbunova V; Vikström A; Scherpereel A; Kim JH; Ahn MJ; Chella A; Chouaid C; Campbell AK; Barlesi F
J Thorac Oncol; 2013 Nov; 8(11):1409-16. PubMed ID: 24077452
[TBL] [Abstract][Full Text] [Related]
49. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
Stark D; Nankivell M; Pujade-Lauraine E; Kristensen G; Elit L; Stockler M; Hilpert F; Cervantes A; Brown J; Lanceley A; Velikova G; Sabate E; Pfisterer J; Carey MS; Beale P; Qian W; Swart AM; Oza A; Perren T
Lancet Oncol; 2013 Mar; 14(3):236-43. PubMed ID: 23333117
[TBL] [Abstract][Full Text] [Related]
50. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD
Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055
[No Abstract] [Full Text] [Related]
51. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; de Oliveira JSR; Buccheri V; Perini GF; Dickinson M; McDonald A; Özcan M; Sekiguchi N; Zhu Y; Raut M; Saretsky TL; Nahar A; Kuruvilla J
Blood Adv; 2022 Jan; 6(2):590-599. PubMed ID: 34644372
[TBL] [Abstract][Full Text] [Related]
52. Platinum sensitivity and non-cross-resistance of cisplatin analogue with cisplatin in recurrent cervical cancer.
Takekuma M; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Gynecol Oncol; 2015 Jul; 26(3):185-92. PubMed ID: 26197856
[TBL] [Abstract][Full Text] [Related]
53. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
Rosenberg JE; Mamtani R; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Sridhar SS; Pappot H; Gurney H; Bedke J; van der Heijden MS; Galli L; Keam B; Masumori N; Meran J; O'Donnell PH; Park SH; Grande E; Sengeløv L; Uemura H; Skaltsa K; Campbell M; Matsangou M; Wu C; Hepp Z; McKay C; Powles T; Petrylak DP
Eur Urol; 2024 Jun; 85(6):574-585. PubMed ID: 38418343
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
[TBL] [Abstract][Full Text] [Related]
55. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
Adenis A; Kulkarni AS; Girotto GC; de la Fouchardiere C; Senellart H; van Laarhoven HWM; Mansoor W; Al-Rajabi R; Norquist J; Amonkar M; Suryawanshi S; Bhagia P; Metges JP
J Clin Oncol; 2022 Feb; 40(4):382-391. PubMed ID: 34730989
[TBL] [Abstract][Full Text] [Related]
56. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
[TBL] [Abstract][Full Text] [Related]
57. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
58. Rapid palliation of symptoms with platinum-based chemotherapy plus cetuximab in recurrent oral cancer: a case report.
Mesía R; Palmero R; Cos M; Vilajosana E; Vázquez S
Head Neck Oncol; 2010 Jan; 2():3. PubMed ID: 20181021
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
60. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Stewart AK; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Buchanan J; Cocks K; Yang X; Xing B; Zojwalla N; Tonda M; Moreau P; Palumbo A
J Clin Oncol; 2016 Nov; 34(32):3921-3930. PubMed ID: 27601539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]